The global Vaccine market was valued at $ 34,826.1 million in 2019 and is anticipated to grow at a CAGR of 9.0% from 2020 to 2027. This growth is attributed to several macro and micro economic factors such as
- Government Investments and Awareness Programs
The increasing emphasis on the health of the nation’s population governments across the countries is working towards improving the health facilities and providing the best of the treatments for their people. With the investments, the nations are also running various awareness campaigns regarding the vaccine curable disease. The best example of the government campaign is the Polio campaign in India where grassroots campaigns organized in various cities and villages of India helped in reducing the number of polio cases through the oral administration of polio vaccine to as many children as possible, escalating the immunization levels significantly against Polio. As of now, India is a polio-free country. The international health assemblies and organizations are also putting several efforts in order to ensure that every stratum of the society, irrespective of social and economic status is granted access to immunization. In 2010 WHO launched the ‘Global Vaccine Action Plan (GVAP)’ that was authorized by 194 member states of the World Health Assembly with the aim of providing individuals and communities healthy lives from vaccine-preventable diseases.
- Improving Health Infrastructure
The vaccine sector represents an increasingly attractive market worldwide supported by strong growth prospects increased research and development activity, emerging economies, increasing public spending, and above all improving health infrastructure. The vaccine market gets benefited through the health infrastructure in the form of establishing medical needs and signifying safety and effectiveness (or immunogenicity) in clinical trials. The healthcare infrastructure helps to obtain marketing authorization (regulatory approval) for commercial launch and development of national recommendations for optimal use. The improving health facilities support securing funding to support vaccine program delivery and providing the necessary infrastructure for vaccine program implementation. Furthermore, it ensures adequate vaccine supply and distribution capacity and assures education of the public and medical community which is extremely necessary for establishing an appropriate infrastructure for vaccine distribution and delivery. Improving economies and government initiatives for the development of high-quality medical infrastructure is expected to boost the vaccine market growth.
- Increasing Prevalence of Chronic Diseases
According to WHO the chronic diseases are expected to rise to 73% of all deaths and 60% of the global burden of disease. Out of which 79% of the deaths attributed to these diseases occur in the developing countries. The government across the globe is working towards strengthening control and prevention measures to counter the spread of chronic disease. Chronic health conditions also increase the risk of serious complications from certain vaccine-preventable diseases resulting in long-term illness, hospitalization, and even death. For instance, the people having diabetes have higher rates of hepatitis B than the rest of the population owing to the spread of disease from the sharing of blood glucose meters, finger stick devices, and other diabetes care equipment. The increasing aging population of the world has increased the health threats of chronic diseases such as cardiovascular disease, cancer, chronic respiratory disease, and diabetes. The vaccines can be developed for treating these chronic diseases as well as the causes of these diseases such as smoking addiction. The vaccines can be developed to induce antibodies against nicotine, angiotensin II, or interleukin-1β (IL-1β) and thus provide a potential treatment of smoking addiction. There are a lot of opportunities in the healthcare and biotechnology market in terms of developing effective vaccines for enhancing the chronic disease treatment technologies which are anticipated to boost the vaccine market growth.
Further several factors restraining the market growth include
- Restraining 1
- Restraining 2
Collaborations and Alliances in the Vaccine market is expected to generate higher avenues during the forecast period.
The COVID-19 pandemic has led to supply chain disruptions leading to supply shortages or lower demand in the Vaccine market. The travel restrictions and social-distancing measures have resulted in a sharp drop in consumer and business spending and this pattern is to continue for some time. The end-user trend and preferences have changed due to the pandemic and have resulted in manufacturers, developers, and service providers to adopt various strategies to stabilize the company.
In terms of COVID 19 impact, the Vaccine market report also includes following data points:
- Impact on Vaccine market size
- End User Trend, Preferences and Budget Impact
- Regulatory Framework/Government Policies
- Key Players Strategy to Tackle Negative Impact/Post-COVID Strategies
- Opportunity in Vaccine market
Key Insight in the report:
The global Vaccine market report covers executive summary, market dynamics, COVID impact & post COVID scenario, market size and forecast, competitive intelligence, market positioning, and product offerings.
Our report covers extensive competitive intelligence which include following data points:
- Business Overview
- Business Segment Data
- Financial Data
- Product Segment Analysis and Specification
- Recent Development and Company Strategy Analysis
- SWOT Analysis
The report covers market sizing and forecasting at the country level as well as at the segment level. Vaccine market is analyzed across below-mentioned different segments:
- Indication
- Pneumococcal Diseases
- DTP
- HPV
- Influenza
- Meningococcal
- Disease
- Polio
- Hepatitis
- Rotavirus
- MMR
- Varicella
- Herpes Zoster
- Ebola
- COVID
- Others
- Application
- Conjugate Vaccines
- Inactivated & Subunit
- Live Attenuated
- Recombinant Vaccines
- Type
- Monovalent Vaccines
- Multivalent Vaccines
Vaccine market is also analyzed across below-mentioned regions/countries:
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- South America
- Middle East & Africa
Some of the key players in of Vaccine market include:
- BAVARIAN NORDIC
- SINOVAC BIOTECH LTD.
- PANACEA BIOTEC
- DYNAVAX TECHNOLOGIES CORPORATION
- BHARAT BIOTECH
- ASTELLAS PHARMA INC
- MERCK & CO., INC.
- SANOFI PASTEUR
- ASTRAZENECA
- SERUM INSTITUTE OF INDIA PVT. LTD.
- VALNEVA
- PFIZER
- MITSUBISHI TANABE PHARMA
- EMERGENT BIOSOLUTIONS INC.
- SEQIRUS (CSL LTD)
- GLAXOSMITHKLINE PLC
- HUALAN BIOLOGICAL ENGINEERING INC
- GRIFOLS
- BIOLOGICAL E. LIMITED
- MEDICAGO
REPORT CONTENT BRIEF:
- High level analysis of the current and future market trends and opportunities
- Detailed analysis on current market drivers, restraining factors, and opportunities in the future
- Vaccine market estimates for 2020 and forecast from 2021 to 2028
- Vendor market share analysis at each product level
- Competitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.
- Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations and partnerships as well as funding taken and investment done, among others.
Target Audience
- Manufacturers
- Suppliers and traders
- Government, associations, and industrial bodies
- Investors and trade experts
- Consulting Firms or Individual Consultant
- Anyone interested in understanding industry dynamic of Vaccine market
